| Literature DB >> 29065931 |
Mikhail Protopopov1, Joachim Sieper1, Hildrun Haibel1, Joachim Listing2, Martin Rudwaleit1,3, Denis Poddubnyy4,5.
Abstract
BACKGROUND: Functional status and spinal mobility in patients with axial spondyloarthritis (axSpA) are known to be determined both by disease activity and by structural damage in the spine. The impact of structural damage in the sacroiliac joints (SIJ) on physical function and spinal mobility in axSpA has not been studied so far. The objective of the study was to analyze the impact of radiographic sacroiliitis on functional status and spinal mobility in patients with axSpA.Entities:
Keywords: Ankylosing spondylitis; Axial spondyloarthritis; BASFI; BASMI; Physical function; Sacroiliitis; Spinal mobility; Structural damage
Mesh:
Year: 2017 PMID: 29065931 PMCID: PMC5655812 DOI: 10.1186/s13075-017-1453-3
Source DB: PubMed Journal: Arthritis Res Ther ISSN: 1478-6354 Impact factor: 5.156
Baseline disease characteristics of 210 patients with axial spondyloarthritis
| Baseline parameters | Nr-axSpA (n = 95) | AS (n = 115) | All patients (n = 210) |
|---|---|---|---|
| Age, years | 38.7 ± 9.9 | 36.8 ± 11.0 | 37.3 ± 10.6 |
| Male gender, | 32 (33.7) | 75 (65.2) | 107 (51.0) |
| HLA-B27 positive, | 69 (72.6) | 97 (84.3) | 166 (79.0) |
| Duration of symptoms, years | 3.2 ± 2.2 | 5.2 ± 2.8 | 4.2 ± 2.7 |
| BASDAI, points NRS (0–10) | 4.2 ± 2.0 | 3.8 ± 2.2 | 3.9 ± 2.2 |
| Peripheral arthritis, | 16 (16.8) | 15 (13.0) | 31 (14.8) |
| BASFI, points NRS (0–10) | 2.8 ± 2.2 | 3.0 ± 2.4 | 2.9 ± 2.3 |
| BASMI, points (0–10) | 1.5 ± 1.5 | 2.0 ± 1.7 | 1.8 ± 1.6 |
| CRP, mg/l | 6.5 ± 12.8 | 12.4 ± 16.6 | 9.7 ± 15.2 |
| mSASSS, points (0–72) | 2.3 ± 4.2 | 5.9 ± 10.3 | 4.2 ± 8.3 |
| NSAIDs intake, | 64 (67.4) | 76 (66.1) | 140 (66.7) |
| Systemic steroids intake, | 6 (6.3) | 6 (5.2) | 12 (5.7) |
| DMARDs intake, | 26 (27.4) | 35 (30.4) | 61 (29.0) |
| TNFα blocker intake, | 1 (1.1) | 4 (3.5) | 5 (2.4) |
| Current smoking, | 24 (25.3) | 39 (33.9) | 63 (30.0) |
Continuous variables are presented as mean ± standard deviation
AS ankylosing spondylitis, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, BASFI Bath Ankylosing Spondylitis Functional Index, BASMI Bath Ankylosing Spondylitis Metrology Index, CRP C-reactive protein, DMARDs disease-modifying anti-rheumatic drugs, mSASSS modified Stoke Ankylosing Spondylitis Spine Score, nr-axSpA non-radiographic axial spondyloarthritis, NRS numeric rating scale, NSAIDs non-steroidal anti-inflammatory drugs, TNFα tumour necrosis factor alpha
Fig. 1Distribution of the sacroiliitis sum score at baseline (a) and change in the sacroiliitis sum score over 2 years (b) in 210 patients with axial spondyloarthritis
Fig. 2Combined cumulative probability and scatter plots depicting an association between the sacroiliitis sum score and the Bath Ankylosing Spondylitis Functional Index (BASFI) (a) or the Bath Ankylosing Spondylitis Metrology Index (BASMI) (b) at baseline in 210 patients with axial spondyloarthritis
Association between the sum radiographic sacroiliitis score and functional status/spinal mobility in patients with axial spondyloarthritis
| Parameters | Unadjusted mixed model analysis (all patients, n = 210), B (95% CI) | Adjusted mixed model analysis (all patients, n = 210), B (95% CI) | Adjusted mixed model analysis (patients with AS, n = 105), B (95% CI) | Adjusted mixed model analysis (patients with nr-axSpA, n = 95), B (95% CI) |
|---|---|---|---|---|
| Outcome: BASFI | ||||
| Sacroiliitis sum score (0–8) | 0.09 (-0.05 to 0.22) |
| 0.16 (-0.03 to 0.36) | 0.09 (-0.11 to 0.30) |
| mSASSS, points (0–72) | - | 0.05 (0.03 to 0.07) | 0.04 (0.02 to 0.06) | 0.08 (0.03 to 0.14) |
| BASDAI, points NRS (0–10) | - | 0.81 (0.74 to 0.88) | 0.84 (0.74 to 0.93) | 0.75 (0.63 to 0.86) |
| CRP, mg/l | - | 0.00 (-0.01 to 0.01) | 0.00 (-0.01 to 0.01) | 0.00 (-0.02 to 0.01) |
| Male sex | - | -0.02 (-0.40 to 0.37) | 0.03 (-0.48 to 0.55) | -0.13 (-0.74 to 0.48) |
| Outcome: BASMI | ||||
| Sacroiliitis sum score (0–8) | 0.20 (0.11 to 0.30) |
| 0.17 (-0.02 to 0.37) | 0.21 (0.01 to 0.40) |
| mSASSS, points (0–72) | - | 0.07 (0.05 to 0.09) | 0.07 (0.04 to 0.09) | 0.04 (-0.01 to 0.10) |
| BASDAI, points NRS (0–10) | - | 0.22 (0.15 to 0.29) | 0.23 (0.14 to 0.32) | 0.18 (0.07 to 0.30) |
| CRP, mg/l | - | 0.01 (0.00 to 0.02) | 0.01 (0.00 to 0.03) | 0.00 (-0.03 to 0.01) |
| Male sex | - | 0.00 (-0.39 to 0.39) | 0.32 (-0.21 to 0.85) | -0.35 (-0.92 to 0.22) |
mSASSS modified Stoke Ankylosing Spondylitis Spine Score, AS Ankylosing Spondylitis, nr-axSpA non-radiographic axial spondyloarthritis, BASFI Bath Ankylosing Spondylitis Functional Index, CRP C-reactive protein, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, NRS numerical rating scale, BASMI Bath Ankylosing Spondylitis Metrology Index
Main results are marked in bold